Binex Co

Binex Co FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Binex Co (053030.KQ) as of Oct 27, 2026 is 1,442.47 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 59.25 % — a change of 2,334.68% (higher).

FCF Conversion

1,442.47 %

YoY

2,334.68%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Binex Co is 2025 1,442.47 % . FCF Conversion Rate (FCF/EBITDA) of Binex Co was 2024 59.25 % . It decreases by 2,334.68% higher compared to the previous year.

The Binex Co FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
173.83 KRW
Jan 1, 2019
23.44 KRW
Jan 1, 2020
190.59 KRW
Jan 1, 2021
84.95 KRW
Jan 1, 2022
-155.82 KRW
Jan 1, 2023
-264.98 KRW
Jan 1, 2024
59.25 KRW
Jan 1, 2025
1,442.47 KRW
The Binex Co FCF Conversion history
YEARFCF ConversionYoY
1,442.47 %+2,334.68%
59.25 %-122.36%
-264.98 %+70.06%
-155.82 %-283.42%
84.95 %-55.43%
190.59 %+712.91%
23.44 %-86.51%
173.83 %-434.56%
-51.96 %-201.37%
51.25 %-93.16%
749.07 %-2,236.97%
-35.05 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Binex Co Stock analysis

What does Binex Co do? Binex Co Ltd generates revenue through the manufacturing and sale of pharmaceutical products including digestive system agents, circulatory system agents, ulcer agents, antacids, anti-inflammatory agents, analgesics, gastrointestinal tract regulators, antispasmodics, antiemetic drugs, antihistamines, laxatives, antihypertensive and urinary agents, antibacterial and antibiotic agents, cough and cold remedies, anti-diabetic medicines, ophthalmic solutions, vitamins, nutrients, and various ointments and creams. The company also produces bio medicines and raw materials. Binex Co Ltd distributes its products domestically within Busan and to overseas markets, targeting healthcare providers, pharmacies, and hospitals that purchase pharmaceuticals for patient care and treatment. The firm's product portfolio covers a wide range of therapeutic areas, including gastrointestinal health, cardiovascular support, pain management, respiratory care, and chronic disease management. By offering both branded and generic pharmaceutical solutions, Binex Co Ltd serves diverse customer segments across the domestic and international pharmaceutical markets, leveraging its manufacturing capabilities to meet regional healthcare demands. Binex Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Binex Co stock

FCF Conversion Rate (FCF/EBITDA) of Binex Co is 1,442.47 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Binex Co changed from 59.25 % to 1,442.47 %, representing a 2,334.68% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Binex Co since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Binex Co with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Cash Flow — Binex Co

Operating Cash FlowCapital ExpendituresFree Cash FlowFCF per ShareDividends PaidShare BuybacksInvesting Cash FlowFinancing Cash FlowCapEx / RevenueCash Flow per ShareStock-Based CompensationChange in Working CapitalAcquisitions (Net)Net Change in CashCapEx/OCFFCF/Net IncomeFCF ConversionCash ConversionTotal Shareholder PayoutCapEx/D&A

All Key Metrics — Binex Co